Chimeric antigen receptor tumor infiltrating lymphocytes
AssigneeH. Lee Moffit Cancer Center and Research Institute, Inc.
InventorsJames Mulé, Daniel Abate-Daga
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for targeted treatment of infections and cancers expressing cancers. In particular, tumor infiltrating lymphocytes (TILs) are genetically engineered to express chimeric antigen receptor (CAR) polypeptides to produce CAR-TILs that can be used with adoptive cell transfer to target, penetrate, and kill solid tumor masses. Therefore, also disclosed are methods of providing an immunotherapy in a subject with an infection or cancer that involves adoptive transfer of the disclosed CAR-TILs.
Claims7
A recombinant lymphocyte produced by a method comprising:
- (a) obtaining and expanding tumor-infiltrating lymphocyte from a mammalian subject;
- and
- (b) genetically engineering the autologous tumor-infiltrating lymphocyte to express a chimeric antigen receptor (CAR),
- wherein the CAR comprises an ectodomain, a transmembrane domain, an intracellular signaling domain, and a co-stimulatory signaling region, and
- wherein the ectodomain comprises a tumor antigen binding agent.
Dependencies are inferred from the claim text.